{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T12:14:19Z","timestamp":1770898459529,"version":"3.50.1"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"51","license":[{"start":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T00:00:00Z","timestamp":1671753600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,12,23]]},"abstract":"<jats:sec>\n            <jats:title>Introduction:<\/jats:title>\n            <jats:p>An increasing number of individuals are taking buprenorphine for management of opioid use disorder (OUD). Pain control can be challenging when these patients develop acute pain requiring supplemental analgesia. Buprenorphine\u2019s pharmacokinetic profile can render supplemental opioid-based analgesia ineffective. There is limited guidance on the optimal management of buprenorphine when acute pain is anticipated. Although there is growing acceptance that the risk of OUD relapse with buprenorphine discontinuation overshadows the risks of increased opioid utilization and difficult pain control with buprenorphine continuation, perioperative courses comparing buprenorphine dose reduction and full dose buprenorphine continuation have yet to be investigated. Here, we describe the protocol for our randomized controlled, prospective trial investigating the effect of buprenorphine continuation compared to buprenorphine dose reduction on pain control, post-operative opioid use, and OUD symptom management in patients on buprenorphine scheduled for elective surgery.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods and analysis:<\/jats:title>\n            <jats:p>This is a single institution, randomized trial that aims to enroll 80 adults using 12\u2009mg buprenorphine or greater for treatment of OUD, scheduled for elective surgery. Participants will be randomly assigned to receive 8mg of buprenorphine on the day of surgery onwards until postsurgical pain subsides or to have their buprenorphine formulation continued at full dose perioperatively. Primary outcome will be a clinically significant difference in pain scores 24 hours following surgery. Secondary outcomes will be opioid consumption at 24, 48, and 72 hours postoperatively, opioid dispensing up to 30 days following surgery, changes in mood and withdrawal symptoms, opioid cravings, relapse of opioid misuse, and continued use of buprenorphine treatment postoperatively.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000032309","type":"journal-article","created":{"date-parts":[[2022,12,27]],"date-time":"2022-12-27T14:04:02Z","timestamp":1672149842000},"page":"e32309","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["A prospective, randomized trial of the effect of buprenorphine continuation versus dose reduction on pain control and post-operative opioid use"],"prefix":"10.1097","volume":"101","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7573-2164","authenticated-orcid":false,"given":"Aurora","family":"Quaye","sequence":"first","affiliation":[{"name":"Department of Anesthesiology and Perioperative Medicine, Maine Medical Center, Portland, ME"},{"name":"Spectrum Healthcare Partners, South Portland, ME"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristen","family":"Silvia","sequence":"additional","affiliation":[{"name":"Division of Addiction Medicine, Maine Medical Center, Portland, ME"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janelle","family":"Richard","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology and Perioperative Medicine, Maine Medical Center, Portland, ME"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yussr","family":"Ibrahim","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology and Perioperative Medicine, Maine Medical Center, Portland, ME"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wendy Y.","family":"Craig","sequence":"additional","affiliation":[{"name":"MaineHealth Institute for Research, Scarborough, ME."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clifford","family":"Rosen","sequence":"additional","affiliation":[{"name":"MaineHealth Institute for Research, Scarborough, ME."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1001\/jama.284.13.1689","article-title":"Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation.","volume":"284","author":"McLellan","year":"2000","journal-title":"JAMA"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1111\/add.15841","article-title":"Exponential growth of drug overdose poisoning and opportunities for intervention.","volume":"117","author":"Jalal","year":"2022","journal-title":"Addiction"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"737","DOI":"10.2105\/AJPH.2010.197038","article-title":"Surviving drug addiction: the effect of treatment and abstinence on mortality.","volume":"101","author":"Scott","year":"2011","journal-title":"Am J Public Health"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1056\/NEJMra1604339","article-title":"Treatment of opioid-use disorders.","volume":"375","author":"Schuckit","year":"2016","journal-title":"N Engl J Med"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1001\/archgenpsychiatry.2011.121","article-title":"Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial.","volume":"68","author":"Weiss","year":"2011","journal-title":"Arch Gen Psychiatry"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s12630-018-1255-3","article-title":"The perioperative patient on buprenorphine: a systematic review of perioperative management strategies and patient outcomes.","volume":"66","author":"Goel","year":"2019","journal-title":"Can J Anaesth"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1093\/pm\/pny019","article-title":"Patients maintained on buprenorphine for opioid use disorder should continue buprenorphine through the perioperative period.","volume":"20","author":"Lembke","year":"2019","journal-title":"Pain Med"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/j.mayocp.2019.10.007","article-title":"A practical approach for the management of the mixed opioid agonist-antagonist buprenorphine during acute pain and surgery.","volume":"95","author":"Warner","year":"2020","journal-title":"Mayo Clin Proc"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.mcna.2021.09.001","article-title":"Perioperative buprenorphine management: a multidisciplinary approach.","volume":"106","author":"Hickey","year":"2022","journal-title":"Med Clin North Am"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1093\/pm\/pnaa020","article-title":"Perioperative continuation of buprenorphine at low-moderate doses was associated with lower postoperative pain scores and decreased outpatient opioid dispensing compared with buprenorphine discontinuation.","volume":"21","author":"Quaye","year":"2020","journal-title":"Pain Med"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1136\/rapm-2021-103007","article-title":"Buprenorphine management in the perioperative period: educational review and recommendations from a multi society expert panel.","volume":"46","author":"Kohan","year":"2021","journal-title":"Reg Anesth Pain Med"},{"key":"R16-20250504","first-page":"E1","article-title":"Buprenorphine formulations: clinical best practice strategies recommendations for perioperative management of patients undergoing surgical or interventional pain procedures.","volume":"21","author":"Jonan","year":"2018","journal-title":"Pain Physician"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1093\/pm\/pny217","article-title":"Perioperative management of buprenorphine: solving the conundrum.","volume":"20","author":"Quaye","year":"2019","journal-title":"Pain Med"},{"issue":"Suppl 1","key":"R18-20250504","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1007\/s00586-005-1044-x","article-title":"Pain assessment.","volume":"15","author":"Haefeli","year":"2006","journal-title":"Eur Spine J"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"200","DOI":"10.7326\/0003-4819-158-3-201302050-00583","article-title":"SPIRIT 2013 statement: defining standard protocol items for clinical trials.","volume":"158","author":"Chan","year":"2013","journal-title":"Ann Intern Med"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1097\/ALN.0b013e31828866b3","article-title":"Pain intensity on the first day after surgery: a prospective cohort study comparing 179 surgical procedures.","volume":"118","author":"Gerbershagen","year":"2013","journal-title":"Anesthesiology"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1046\/j.1525-1497.2001.016009606.x","article-title":"The PHQ-9: validity of a brief depression severity measure.","volume":"16","author":"Kroenke","year":"2001","journal-title":"J Gen Intern Med"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1093\/pm\/pnx311","article-title":"Development of a brief version of the current opioid misuse measure (COMM): the COMM-9.","volume":"20","author":"McCaffrey","year":"2019","journal-title":"Pain Med"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"106651","DOI":"10.1016\/j.addbeh.2020.106651","article-title":"Validation of the craving scale in a large sample of adults with substance use disorders.","volume":"113","author":"McHugh","year":"2021","journal-title":"Addict Behav"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1080\/02791072.2003.10400007","article-title":"The clinical opiate withdrawal scale (COWS).","volume":"35","author":"Wesson","year":"2003","journal-title":"J Psychoactive Drugs"},{"key":"R25-20250504","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1080\/00952990.2018.1469138","article-title":"Timeline: a web application for assessing the timing and details of health behaviors.","volume":"45","author":"Wray","year":"2019","journal-title":"Am J Drug Alcohol Abuse"},{"key":"R26-20250504","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1097\/BRS.0b013e31815e3a10","article-title":"Interpreting change scores for pain and functional status in low back pain: towards international consensus regarding minimal important change.","volume":"33","author":"Ostelo","year":"2008","journal-title":"Spine."}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000032309","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T05:24:14Z","timestamp":1746336254000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000032309"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,23]]},"references-count":22,"journal-issue":{"issue":"51","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000032309","relation":{},"ISSN":["1536-5964"],"issn-type":[{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,23]]}}}